Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/access-and-inequality.md — the filesystem corpus, unchanged. Not an edit.
14.0 kB
Revision 1
Revision 2
lines 7–13 → 7–136 unchanged lines not shown
categories: ["society"]categories: ["society"]tags: ["justice", "pricing", "policy", "gene therapy", "global health", "equity"]tags: ["justice", "pricing", "policy", "gene therapy", "global health", "equity"]summary: "The problem of who can obtain expensive biomedical interventions, and whether biotechnology will convert economic inequality into biological inequality."summary: "The problem of who can obtain expensive biomedical interventions, and whether biotechnology will convert economic inequality into biological inequality."updated: "2026-07-27"updated: "2026-10-29"issues: ["The gene therapy list prices in the opening section are given without citations.", "The 2024 CMS outcomes-based purchasing model for sickle cell is stated without a source."]issues: ["The gene therapy list prices in the opening section are given without citations.", "The 2024 CMS outcomes-based purchasing model for sickle cell is stated without a source."]------ lines 25–31 → 25–3111 unchanged lines not shown
}}`````` **Access and inequality** names the question of who actually receives a biomedical intervention once it works, and the associated worry that technologies capable of altering bodies and minds will translate existing economic stratification into biological stratification. The concern is old in the literature and recent in practice: until the 2010s no medicine cost enough to make it acute. As of 2026 several licensed therapies are priced above two million dollars per patient, and the mismatch between where the diseases are and where the treatments are delivered is the central unsolved problem of the genetic-medicine era.**Access and inequality** names the question of who actually receives a biomedical intervention once it works, and the associated worry that technologies capable of altering bodies and minds will translate existing economic stratification into biological stratification. The concern is old in the literature and recent in practice: until the 2010s no medicine cost enough to make it acute. As of 2026 several licensed therapies are priced above two million dollars per patient. The mismatch between where the diseases are and where the treatments are delivered is the central unsolved problem of the genetic-medicine era. ```keyfacts```keyfacts[[lines 37–56 → 37–565 unchanged lines not shown
## The arithmetic of a one-time cure## The arithmetic of a one-time cure Conventional pharmaceutical pricing spreads cost over years of dosing. A cure delivered once has to recover its development cost in a single transaction, and the manufacturer's incentive is to price against the lifetime cost of the disease it displaces rather than against the cost of goods. That logic produced the current price ladder: onasemnogene abeparvovec for spinal muscular atrophy at roughly $2.1 million on US launch in 2019, etranacogene dezaparvovec for haemophilia B at roughly $3.5 million in 2022, and atidarsagene autotemcel for metachromatic leukodystrophy at roughly $4.25 million in 2024 — the highest list price ever set for a medicine. [[casgevy]] and a competing lentiviral product for sickle cell disease were approved in the United States in December 2023 at roughly $2.2 million and $3.1 million respectively.Conventional pharmaceutical pricing spreads cost over years of dosing. A cure delivered once has to recover its development cost in a single transaction, so the manufacturer's incentive is to price it against the lifetime cost of the disease it displaces rather than against the cost of goods. That logic produced the current price ladder. Onasemnogene abeparvovec for spinal muscular atrophy launched in the US in 2019 at roughly $2.1 million, etranacogene dezaparvovec for haemophilia B at roughly $3.5 million in 2022, and atidarsagene autotemcel for metachromatic leukodystrophy at roughly $4.25 million in 2024, the highest list price ever set for a medicine. [[casgevy]] and a competing lentiviral product for sickle cell disease were approved in the United States in December 2023 at roughly $2.2 million and $3.1 million respectively. Health economists have generally judged several of these prices defensible on cost-effectiveness grounds, because the alternative is decades of transfusions, factor concentrate, or intensive care. That defence does not answer the budget-impact problem. A public payer facing a hundred eligible patients in one year confronts a bill it cannot smooth, and the treatments are concentrated in exactly the populations — children with rare inherited disease, adults with sickle cell — least able to negotiate.Health economists have generally judged several of these prices defensible on cost-effectiveness grounds, because the alternative is decades of transfusions, factor concentrate, or intensive care. That defence leaves the budget-impact problem untouched. A public payer facing a hundred eligible patients in one year confronts a bill it cannot smooth, and the treatments are concentrated in the populations least able to negotiate: children with rare inherited disease and adults with sickle cell. The commercial results have been poor for everyone. The first gene therapy licensed in Europe was withdrawn in 2017 after a single commercial course was sold. Two later products were pulled from European markets in 2021 when their maker could not agree prices with national payers, leaving patients in countries where the therapy was licensed with no route to receiving it. Approval and access are separate events, and the gap between them has widened.Commercially, the record has been poor for everyone. The first gene therapy licensed in Europe was withdrawn in 2017 after a single commercial course was sold. Two later products were pulled from European markets in 2021 when their maker could not agree prices with national payers, leaving patients in countries where the therapy was licensed with no route to receiving it. Approval and access are separate events, and the gap between them has widened. > [!key] Why price is not the only barrier> [!key] Why price is not the only barrier> An autologous CRISPR therapy for sickle cell requires apheresis, a manufacturing round trip, and myeloablative conditioning with busulfan followed by weeks of inpatient care. Even at zero drug cost it needs a transplant-capable centre, a cell-processing facility, and a blood bank. Most of the world's sickle cell patients live where none of these exist.> An autologous CRISPR therapy for sickle cell requires apheresis, a manufacturing round trip, and myeloablative conditioning with busulfan followed by weeks of inpatient care. Even at zero drug cost it needs a transplant-capable centre, a cell-processing facility, and a blood bank. Most of the world's sickle cell patients live where none of these exist. ## Where the diseases are## Where the diseases are Sickle cell disease is the clearest case because the mismatch is total. The overwhelming majority of affected births occur in sub-Saharan Africa, with India accounting for much of the remainder;[^piel2017] the approved [[somatic-gene-therapy]] products are administered almost entirely in North America, Europe, and the Gulf. A curative technology has been developed for a disease of the global South and deployed in the global North, and the constraint is not patents alone but the absence of the delivery infrastructure the therapy assumes.Sickle cell disease is the clearest case because the mismatch is total. The overwhelming majority of affected births occur in sub-Saharan Africa, with India accounting for much of the remainder;[^piel2017] the approved [[somatic-gene-therapy]] products are administered almost entirely in North America, Europe, and the Gulf. A curative technology has been developed for a disease of the global South and deployed in the global North. Patents are one constraint; the other is the absence of the delivery infrastructure that the therapy assumes. The same structure recurs across the wiki's subject matter. [[cochlear-implant]] surgery is routine in high-income countries and rare in most low-income ones, where the majority of children with profound congenital deafness live. [[organ-shortage]] is managed by transplant systems that only some states can operate. The devices described in [[brain-computer-interface]] research require neurosurgical centres and years of technical support per patient. The largest instance by volume is not a one-time cure at all: [[glp-1-receptor-agonists|incretin drugs]] for obesity and diabetes carry US list prices on the order of a thousand dollars a month, and obesity prevalence is rising fastest in the middle-income countries where they are furthest out of reach.The same structure recurs across the wiki's subject matter. [[cochlear-implant]] surgery is routine in high-income countries and rare in most low-income ones, where the majority of children with profound congenital deafness live. [[organ-shortage]] is managed by transplant systems that only some states can operate. The devices described in [[brain-computer-interface]] research require neurosurgical centres and years of technical support per patient. By volume, the largest instance is not a one-time cure at all: [[glp-1-receptor-agonists|incretin drugs]] for obesity and diabetes carry US list prices on the order of a thousand dollars a month, and obesity prevalence is rising fastest in the middle-income countries where they are furthest out of reach. ## The historical record on diffusion## The historical record on diffusion lines 58–95 → 58–951 unchanged line not shown
Antiretroviral therapy for HIV cost well over ten thousand dollars per patient per year in 2000 and was, on standard analysis, permanently out of reach for African health systems. Within roughly a decade generic fixed-dose combinations manufactured in India, mass procurement through the Global Fund and PEPFAR, and voluntary licensing had brought first-line regimens to a small fraction of that figure, and tens of millions of people were on treatment.[^msf] Direct-acting antivirals for hepatitis C followed a compressed version of the same path: a US list price of tens of thousands of dollars per course alongside voluntary licences that put courses in some low- and middle-income countries at a few hundred dollars.Antiretroviral therapy for HIV cost well over ten thousand dollars per patient per year in 2000 and was, on standard analysis, permanently out of reach for African health systems. Within roughly a decade generic fixed-dose combinations manufactured in India, mass procurement through the Global Fund and PEPFAR, and voluntary licensing had brought first-line regimens to a small fraction of that figure, and tens of millions of people were on treatment.[^msf] Direct-acting antivirals for hepatitis C followed a compressed version of the same path: a US list price of tens of thousands of dollars per course alongside voluntary licences that put courses in some low- and middle-income countries at a few hundred dollars. Three features made those cases tractable, and all three are absent for cell and gene therapy. The products were small molecules that generic manufacturers could copy at scale. Administration required only a clinic and a pill. And the epidemic's size created political pressure sufficient to override ordinary intellectual-property arrangements.Three features made those cases tractable, and cell and gene therapy has none of them. The products were small molecules that generic manufacturers could copy at scale. Administration required only a clinic and a pill. The epidemic was large enough to create political pressure that overrode ordinary intellectual-property arrangements. Autologous cell therapy has none of those properties. Each dose is manufactured for one patient, so unit cost does not fall the way chemical synthesis does. The bottleneck is process and facility, not molecule. And the affected populations, though large in aggregate, are politically fragmented across dozens of rare conditions.Autologous cell therapy differs on each count. Every dose is manufactured for one patient, so unit cost does not fall the way it does in chemical synthesis. The bottleneck lies in the process and the facility rather than the molecule. The affected populations, though large in aggregate, are politically fragmented across dozens of rare conditions. Against this, the cost of reading a genome fell from roughly a hundred million dollars in 2001 to a few hundred, one of the steepest cost declines recorded in any technology.[^nhgri] That curve is often cited as evidence that therapy costs will follow. It is a poor analogy: sequencing is an instrument-and-reagent problem subject to semiconductor-like scaling, while manufacturing a cell product is closer to running a small hospital.Against this, the cost of reading a genome fell from roughly a hundred million dollars in 2001 to a few hundred, one of the steepest cost declines recorded in any technology.[^nhgri] That curve is often cited as evidence that therapy costs will follow, but the analogy is poor: sequencing is an instrument-and-reagent problem subject to semiconductor-like scaling, while manufacturing a cell product is closer to running a small hospital. ## What could change the curve## What could change the curve Three technical shifts would alter the economics rather than the pricing negotiation.Three technical shifts would alter the economics rather than the pricing negotiation. **In vivo editing.** Delivering an editor directly to the patient removes cell collection, manufacturing, and conditioning at a stroke. [[lipid-nanoparticles]] carrying CRISPR components have been used systemically in humans, and the first bespoke therapy for a single infant with a urea-cycle disorder was designed and dosed within months in 2025 — a demonstration that the regulatory and manufacturing path can be compressed, though at a cost per patient that no system could generalise. Whether in vivo editing reaches the tissues that matter for sickle cell is unresolved; the target is the haematopoietic stem cell, and reaching it in the marrow is harder than reaching the liver.**In vivo editing.** Delivering an editor directly to the patient removes cell collection, manufacturing, and conditioning at a stroke. [[lipid-nanoparticles]] carrying CRISPR components have been used systemically in humans, and the first bespoke therapy for a single infant with a urea-cycle disorder was designed and dosed within months in 2025. The case showed that the regulatory and manufacturing path can be compressed, though at a cost per patient that no system could generalise. Whether in vivo editing reaches the tissues that matter for sickle cell is unresolved; the target is the haematopoietic stem cell, and reaching it in the marrow is harder than reaching the liver. **Allogeneic and off-the-shelf products.** A cell therapy manufactured in batches from donor material amortises across many patients. This is the main cost lever in the CAR-T field and applies in principle to regenerative products built on [[induced-pluripotent-stem-cells]].**Allogeneic and off-the-shelf products.** A cell therapy manufactured in batches from donor material amortises across many patients. This is the main cost lever in the CAR-T field and applies in principle to regenerative products built on [[induced-pluripotent-stem-cells]]. **Cheap geroprotection.** If the interventions that come out of the [[geroscience-hypothesis]] turn out to be repurposed generics, the distributive picture inverts. [[metformin]] costs pennies. [[exercise-and-aging]] describes the best-evidenced intervention available, which costs nothing and is nonetheless distributed with a steep social gradient — a reminder that price is not the binding constraint on health inequality, and never has been.**Cheap geroprotection.** If the interventions that come out of the [[geroscience-hypothesis]] turn out to be repurposed generics, the distributive picture inverts. [[metformin]] costs pennies. [[exercise-and-aging]] describes the best-evidenced intervention available, which costs nothing and is still distributed with a steep social gradient. Price is not the binding constraint on health inequality, and never has been. ## Policy responses## Policy responses Payers have experimented with instruments that spread or condition payment. Outcomes-based agreements make part of the price contingent on durable benefit, which fits one-time therapies well in principle and requires long-term follow-up data that health systems are poorly equipped to collect. Subscription or "Netflix" arrangements, in which a payer buys unlimited access for a fixed annual fee, were adopted by two US states for hepatitis C treatment in 2019 and sharply increased the number of people treated in their prison and Medicaid populations. In 2024 the US Centers for Medicare and Medicaid Services announced a multi-state outcomes-based purchasing model specifically for sickle cell gene therapy, with participation beginning in 2025 — the first attempt to negotiate a gene therapy price on behalf of a public programme at national scale.Payers have experimented with instruments that spread or condition payment. Outcomes-based agreements make part of the price contingent on durable benefit, which fits one-time therapies well in principle and requires long-term follow-up data that health systems are poorly equipped to collect. Subscription or "Netflix" arrangements, in which a payer buys unlimited access for a fixed annual fee, were adopted by two US states for hepatitis C treatment in 2019 and sharply increased the number of people treated in their prison and Medicaid populations. In 2024 the US Centers for Medicare and Medicaid Services announced a multi-state outcomes-based purchasing model specifically for sickle cell gene therapy, with participation beginning in 2025. It was the first attempt to negotiate a gene therapy price on behalf of a public programme at national scale. Compulsory licensing under the TRIPS agreement and the 2001 Doha declaration remains available and is almost never used for biologics, partly because a licence to the patent does not transfer the manufacturing know-how, which is the actual barrier. Regional manufacturing initiatives — mRNA technology transfer hubs, African vaccine production capacity — address that barrier directly and operate on a decadal timescale.Compulsory licensing under the TRIPS agreement and the 2001 Doha declaration remains available and is almost never used for biologics. Part of the reason is that a licence to the patent does not transfer the manufacturing know-how, which is the actual barrier. Regional manufacturing initiatives, such as the mRNA technology transfer hubs and efforts to build African vaccine production capacity, address that barrier directly and operate on a decadal timescale. ## The stratification argument## The stratification argument The specifically futurist worry is not about access to cures but about heritable advantage. Lee Silver's 1997 scenario of a society splitting into genetically enhanced and unenhanced lineages remains the reference version, and it depends on premises that have aged unevenly.[^silver1997]The specifically futurist worry concerns heritable advantage rather than access to cures. Lee Silver's 1997 scenario of a society splitting into genetically enhanced and unenhanced lineages remains the reference version, and it depends on premises that have aged unevenly.[^silver1997] The premise that has held is that expensive medicine reaches the wealthy first. The premise that has not held is that genetic enhancement would deliver large, heritable, purchasable advantage. [[genetic-enhancement-of-intelligence]] explains why: the traits people would pay for are highly polygenic, and the achievable shift from [[polygenic-embryo-screening]] is on the order of a fraction of a standard deviation under favourable assumptions, smaller across ancestries not represented in the training data, and not obviously larger than the effect of the environment money already buys. [[germline-editing]] could in principle do more, but not for polygenic traits, and its clinical use remains prohibited in most jurisdictions.The premise that has held is that expensive medicine reaches the wealthy first. The premise that has not held is that genetic enhancement would deliver large, heritable, purchasable advantage. [[genetic-enhancement-of-intelligence]] explains why: the traits people would pay for are highly polygenic, and the achievable shift from [[polygenic-embryo-screening]] is on the order of a fraction of a standard deviation under favourable assumptions, smaller across ancestries not represented in the training data, and not obviously larger than the effect of the environment money already buys. [[germline-editing]] could in principle do more, but not for polygenic traits, and its clinical use remains prohibited in most jurisdictions. > [!debate] Which inequality is the live one> [!debate] Which inequality is the live one> Some argue the genetic-divide scenario distracts from the inequality that exists now: a difference of a decade or more in life expectancy between rich and poor districts of the same city, produced by ordinary causes and requiring no new technology. Others reply that a stratification which becomes heritable is categorically different from one that resets each generation, and is worth preventing before it is cheap.> Some argue the genetic-divide scenario distracts from the inequality that exists now: a difference of a decade or more in life expectancy between rich and poor districts of the same city, produced by ordinary causes and requiring no new technology. Others reply that a stratification which becomes heritable is categorically different from one that resets each generation, and is worth preventing before it is cheap. Both readings agree on the near-term implication. The interventions plausibly capable of stratifying a population — screening, [[embryo-selection]], [[in-vitro-gametogenesis]] if it matures — are lightly regulated in most countries precisely because they involve selection rather than modification, and therefore fall outside the instruments described in [[governance-of-genome-editing]]. The technologies that ethics has watched most closely are not the ones distributing advantage.Both readings agree on the near-term implication. The interventions plausibly capable of stratifying a population are screening, [[embryo-selection]] and, if it matures, [[in-vitro-gametogenesis]]. They are lightly regulated in most countries because they involve selection rather than modification, which places them outside the instruments described in [[governance-of-genome-editing]]. The technologies that ethics has watched most closely are therefore not the ones distributing advantage. ## Open questions## Open questions removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
99 lines are the same in both revisions, and 43 of them are not shown. Neither revision here is necessarily the current article — read Access and inequality for the text this wiki stands behind today.